Abstract 218: Evaluating Thrombectomy Candidacy in Large Core Strokes: Lessons from the SELECT2 Trial at Our Institution

Introduction Reperfusion therapy for patients with large vessel occlusion stroke includes thrombolytics and mechanical thrombectomy. Candidacy for thrombectomy depends on patient factors under active investigation. Historically, patients with large strokes have been excluded from major trials evalua...

Full description

Bibliographic Details
Main Authors: Mohammad Khasawneh, Eve Moll, Brendan Eby, Laura Heitsch
Format: Article
Language:English
Published: Wiley 2023-11-01
Series:Stroke: Vascular and Interventional Neurology
Online Access:https://www.ahajournals.org/doi/10.1161/SVIN.03.suppl_2.218
_version_ 1797221226386554880
author Mohammad Khasawneh
Eve Moll
Brendan Eby
Laura Heitsch
author_facet Mohammad Khasawneh
Eve Moll
Brendan Eby
Laura Heitsch
author_sort Mohammad Khasawneh
collection DOAJ
description Introduction Reperfusion therapy for patients with large vessel occlusion stroke includes thrombolytics and mechanical thrombectomy. Candidacy for thrombectomy depends on patient factors under active investigation. Historically, patients with large strokes have been excluded from major trials evaluating thrombectomy due to concern that thrombectomy would pose considerable risk with limited benefit. However, new evidence from the Select‐2 Trial found improved modified Rankin scale scores and higher rates of functional independence at 90 days following large stroke in patients who underwent thrombectomy versus medical therapy alone. We explored if patients presenting with large stroke at our institution resemble those in the Select‐2 Trial and, how many previously excluded patients could have possibly benefitted from thrombectomy. Methods Patients presenting as a code stroke at our institution from 1/2022 to 7/2022 were retrospectively analyzed. Large strokes, defined as CTP volume greater than 50mL, were identified. Background information included age, sex, race, and prior stroke. Regarding patient stroke presentation, the following data were gathered: NIHSS, LVO status, CTA results, CTP, tPA, thrombectomy status, TICI score, and discharge status. Our patients included in this study were compared to the patients included the Select‐2 Trial. Mortality rates and NIHSS at discharge were compared between thrombectomized and non‐thrombectomized patients at our institution. Results Of the 365 code strokes activated at our institution during the study period, 26 met criteria for a large stroke. Of those 26, 13 met all criteria for inclusion in SELECT‐2. Only 9 of the 26 patients received thrombectomy, including 7 of 13 patients otherwise meeting SELECT‐2 criteria. 6 patients were excluded from thrombectomy who would have met criteria for SELECT‐2. Of the 9 who underwent thrombectomy, one expired, and the average NIHSS calculated from physical exam at discharge of surviving patients was 13. Of the 17 who did not undergo thrombectomy, seven expired and the average NIHSS at discharge was 19.4. Of large stroke patients, average age was 69.5 years (SD 11.0), similar to Select‐2 (median age 66). Average NIHSS at presentation was 19 (SD 6.55), similar to Select 2. Compared to SELECT2 enrollment, our patients were more likely to be female (50% vs 41%), Black (50% vs 25%), have a history of prior stroke (38% vs. 9%). LVO was identified on 23 of 26 patients. Of these 23, 17 MCA, 3 ACA, 6 ICA, and 2 carotid terminus occlusions were identified (6 had tandem occlusions). The average rCBF volume was 102.3 mL (SD 64.3) compared to median estimated ischemic core volume of 80mL in Select 2. Conclusion The patients presenting to our institution with large stroke resemble those included in the Select 2 trial, which demonstrates positive outcomes following mechanical thrombectomy for this special population. Patients with large strokes are frequently excluded from receiving treatment with mechanical thrombectomy. Analysis of a larger data set, including large stroke patients from 2018 to 2022, is currently pending. In light of the Select 2 trial, patients in our community and in our referral basis stand to benefit from an institutional practice of offering thrombectomy to those presenting with large stroke.
first_indexed 2024-03-07T15:37:50Z
format Article
id doaj.art-a0aeb02bb36d48298cca9174e0ea9eff
institution Directory Open Access Journal
issn 2694-5746
language English
last_indexed 2024-04-24T13:02:04Z
publishDate 2023-11-01
publisher Wiley
record_format Article
series Stroke: Vascular and Interventional Neurology
spelling doaj.art-a0aeb02bb36d48298cca9174e0ea9eff2024-04-05T10:51:58ZengWileyStroke: Vascular and Interventional Neurology2694-57462023-11-013S210.1161/SVIN.03.suppl_2.218Abstract 218: Evaluating Thrombectomy Candidacy in Large Core Strokes: Lessons from the SELECT2 Trial at Our InstitutionMohammad Khasawneh0Eve Moll1Brendan Eby2Laura Heitsch3Washington University in St. Louis Missouri United StatesWashington University in St. Louis Missouri United StatesWashington University in St. Louis Missouri United StatesWashington University in St. Louis Missouri United StatesIntroduction Reperfusion therapy for patients with large vessel occlusion stroke includes thrombolytics and mechanical thrombectomy. Candidacy for thrombectomy depends on patient factors under active investigation. Historically, patients with large strokes have been excluded from major trials evaluating thrombectomy due to concern that thrombectomy would pose considerable risk with limited benefit. However, new evidence from the Select‐2 Trial found improved modified Rankin scale scores and higher rates of functional independence at 90 days following large stroke in patients who underwent thrombectomy versus medical therapy alone. We explored if patients presenting with large stroke at our institution resemble those in the Select‐2 Trial and, how many previously excluded patients could have possibly benefitted from thrombectomy. Methods Patients presenting as a code stroke at our institution from 1/2022 to 7/2022 were retrospectively analyzed. Large strokes, defined as CTP volume greater than 50mL, were identified. Background information included age, sex, race, and prior stroke. Regarding patient stroke presentation, the following data were gathered: NIHSS, LVO status, CTA results, CTP, tPA, thrombectomy status, TICI score, and discharge status. Our patients included in this study were compared to the patients included the Select‐2 Trial. Mortality rates and NIHSS at discharge were compared between thrombectomized and non‐thrombectomized patients at our institution. Results Of the 365 code strokes activated at our institution during the study period, 26 met criteria for a large stroke. Of those 26, 13 met all criteria for inclusion in SELECT‐2. Only 9 of the 26 patients received thrombectomy, including 7 of 13 patients otherwise meeting SELECT‐2 criteria. 6 patients were excluded from thrombectomy who would have met criteria for SELECT‐2. Of the 9 who underwent thrombectomy, one expired, and the average NIHSS calculated from physical exam at discharge of surviving patients was 13. Of the 17 who did not undergo thrombectomy, seven expired and the average NIHSS at discharge was 19.4. Of large stroke patients, average age was 69.5 years (SD 11.0), similar to Select‐2 (median age 66). Average NIHSS at presentation was 19 (SD 6.55), similar to Select 2. Compared to SELECT2 enrollment, our patients were more likely to be female (50% vs 41%), Black (50% vs 25%), have a history of prior stroke (38% vs. 9%). LVO was identified on 23 of 26 patients. Of these 23, 17 MCA, 3 ACA, 6 ICA, and 2 carotid terminus occlusions were identified (6 had tandem occlusions). The average rCBF volume was 102.3 mL (SD 64.3) compared to median estimated ischemic core volume of 80mL in Select 2. Conclusion The patients presenting to our institution with large stroke resemble those included in the Select 2 trial, which demonstrates positive outcomes following mechanical thrombectomy for this special population. Patients with large strokes are frequently excluded from receiving treatment with mechanical thrombectomy. Analysis of a larger data set, including large stroke patients from 2018 to 2022, is currently pending. In light of the Select 2 trial, patients in our community and in our referral basis stand to benefit from an institutional practice of offering thrombectomy to those presenting with large stroke.https://www.ahajournals.org/doi/10.1161/SVIN.03.suppl_2.218
spellingShingle Mohammad Khasawneh
Eve Moll
Brendan Eby
Laura Heitsch
Abstract 218: Evaluating Thrombectomy Candidacy in Large Core Strokes: Lessons from the SELECT2 Trial at Our Institution
Stroke: Vascular and Interventional Neurology
title Abstract 218: Evaluating Thrombectomy Candidacy in Large Core Strokes: Lessons from the SELECT2 Trial at Our Institution
title_full Abstract 218: Evaluating Thrombectomy Candidacy in Large Core Strokes: Lessons from the SELECT2 Trial at Our Institution
title_fullStr Abstract 218: Evaluating Thrombectomy Candidacy in Large Core Strokes: Lessons from the SELECT2 Trial at Our Institution
title_full_unstemmed Abstract 218: Evaluating Thrombectomy Candidacy in Large Core Strokes: Lessons from the SELECT2 Trial at Our Institution
title_short Abstract 218: Evaluating Thrombectomy Candidacy in Large Core Strokes: Lessons from the SELECT2 Trial at Our Institution
title_sort abstract 218 evaluating thrombectomy candidacy in large core strokes lessons from the select2 trial at our institution
url https://www.ahajournals.org/doi/10.1161/SVIN.03.suppl_2.218
work_keys_str_mv AT mohammadkhasawneh abstract218evaluatingthrombectomycandidacyinlargecorestrokeslessonsfromtheselect2trialatourinstitution
AT evemoll abstract218evaluatingthrombectomycandidacyinlargecorestrokeslessonsfromtheselect2trialatourinstitution
AT brendaneby abstract218evaluatingthrombectomycandidacyinlargecorestrokeslessonsfromtheselect2trialatourinstitution
AT lauraheitsch abstract218evaluatingthrombectomycandidacyinlargecorestrokeslessonsfromtheselect2trialatourinstitution